Seraph Biosciences
Seraph Biosciences is a biotechnology company dedicated to developing disruptive biomedical solutions, including the Seraspec® platform, a Raman spectroscopy-based pathogen detection technology. Their mission is to provide real-time, point-of-care pathogen identification to improve healthcare outcomes and combat antimicrobial resistance.
Industries
Nr. of Employees
small (1-50)
Seraph Biosciences
Patents
Products
Raman spectroscopy-based pathogen identification platform
A miniaturized, fully automated diagnostic instrument that acquires Raman spectra from clinical samples, matches molecular fingerprints against a reference library, and returns rapid pathogen identification without biological reagents.
Raman spectroscopy-based pathogen identification platform
A miniaturized, fully automated diagnostic instrument that acquires Raman spectra from clinical samples, matches molecular fingerprints against a reference library, and returns rapid pathogen identification without biological reagents.
Services
Program management and execution of assay development, protocol standardization, mentoring of lab staff, and preparation of data for regulatory filings.
Final DFM activities, supplier evaluation, process qualification, documentation of design verification/validation, and production readiness for instruments and disposable components.
Architecture and implementation of embedded device code, secure databases, cloud services, DevOps practices, and software QA for high-availability diagnostic instruments.
Regulatory planning, pre-submission activities, and support for EUA and traditional FDA pathways, informed by participation in government diagnostic acceleration programs.
Development and execution of exclusive distribution and licensing agreements to bring diagnostic instruments to veterinary markets as an initial revenue channel.
Program management and execution of assay development, protocol standardization, mentoring of lab staff, and preparation of data for regulatory filings.
Final DFM activities, supplier evaluation, process qualification, documentation of design verification/validation, and production readiness for instruments and disposable components.
Architecture and implementation of embedded device code, secure databases, cloud services, DevOps practices, and software QA for high-availability diagnostic instruments.
Regulatory planning, pre-submission activities, and support for EUA and traditional FDA pathways, informed by participation in government diagnostic acceleration programs.
Development and execution of exclusive distribution and licensing agreements to bring diagnostic instruments to veterinary markets as an initial revenue channel.
Expertise Areas
- Point-of-care diagnostic development
- Clinical study design and management for IVDs
- Assay and assayless diagnostic R&D
- Device design transfer and manufacturing scale-up
Key Technologies
- Raman spectroscopy
- Spectral fingerprint databases
- Machine learning / deep learning for spectral classification
- Cloud architecture and microservices (AWS)
News & Updates
Seraph seated Dr. Hür Koser on its Board of Directors.
Dr. Hür Köser, an accomplished academic researcher and technical entrepreneur, joined Seraph’s management team as Chief Product and Technology Officer.
Dr. Richard S. Creager, an established executive and consultant in the In Vitro Diagnostics (IVD) industry, joined Seraph’s Board of Directors.
Dr. Nadeem Ishaque, former Chief Innovation Officer of GE Healthcare, joined Seraph’s Board of Directors.
Seraph Biosciences was selected by NIH as a RADx participant to develop COVID-19 diagnostic solutions.
Shane Trexler, Vice President of Engineering, gave an interview about Seraph’s work.
Seraph seated Dr. Hür Koser on its Board of Directors.
Dr. Hür Köser, an accomplished academic researcher and technical entrepreneur, joined Seraph’s management team as Chief Product and Technology Officer.
Dr. Richard S. Creager, an established executive and consultant in the In Vitro Diagnostics (IVD) industry, joined Seraph’s Board of Directors.
Dr. Nadeem Ishaque, former Chief Innovation Officer of GE Healthcare, joined Seraph’s Board of Directors.
Seraph Biosciences was selected by NIH as a RADx participant to develop COVID-19 diagnostic solutions.
Shane Trexler, Vice President of Engineering, gave an interview about Seraph’s work.